ISPOR - EE168 Cost-Effectiveness Analysis of Darolutamide Plus Androgen Deprivation Therapy for Patients With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China

EE168 Cost-Effectiveness Analysis of Darolutamide Plus Androgen Deprivation Therapy for Patients With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China

Abstract

Authors

J Ming Y Wu L Han X Xu R Waldeck S Hu

Full Text Cite This Article

Back to Volume 25, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now